We know two things about using proton beam therapy for focused tumor ablation: 1) it’s less messier than traditional radiation therapy and 2) it sounds cool to say. So we’re pleased that Hitachi is moving forward with their proton beam system, the ProBeat:
Hitachi Ltd.’s U.S. subsidiary said Tuesday it has obtained Food and Drug Administration approval to commercialize its Probeat medical device to treat cancer.
The Probeat system is in the final stages of development at the University of Texas M.D. Anderson Cancer Proton Therapy Center in Houston, the company said. The clinic plans to begin using Probeat to treat patients in May, it added.